These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

936 related items for PubMed ID: 11207317

  • 1. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.
    J Immunol; 2001 Mar 01; 166(5):3564-73. PubMed ID: 11207317
    [Abstract] [Full Text] [Related]

  • 2. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
    Yang S, Haluska FG.
    J Immunol; 2004 Apr 01; 172(7):4599-608. PubMed ID: 15034078
    [Abstract] [Full Text] [Related]

  • 3. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
    J Immunol; 2002 Apr 01; 168(7):3484-92. PubMed ID: 11907109
    [Abstract] [Full Text] [Related]

  • 4. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P, Ng CP, Belldegrun A, Bonavida B.
    Cell Immunol; 1997 Aug 25; 180(1):70-83. PubMed ID: 9316641
    [Abstract] [Full Text] [Related]

  • 5. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G.
    J Immunol; 1998 Aug 01; 161(3):1220-30. PubMed ID: 9686582
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
    Frost PJ, Belldegrun A, Bonavida B.
    Prostate; 1999 Sep 15; 41(1):20-30. PubMed ID: 10440872
    [Abstract] [Full Text] [Related]

  • 9. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
    Bergmann-Leitner ES, Abrams SI.
    J Immunol; 2000 May 01; 164(9):4941-54. PubMed ID: 10779805
    [Abstract] [Full Text] [Related]

  • 10. ECH, an epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.
    Mitsui T, Miyake Y, Kakeya H, Osada H, Kataoka T.
    J Immunol; 2004 Mar 15; 172(6):3428-36. PubMed ID: 15004142
    [Abstract] [Full Text] [Related]

  • 11. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
    Aung S, Graham BS.
    J Immunol; 2000 Apr 01; 164(7):3487-93. PubMed ID: 10725701
    [Abstract] [Full Text] [Related]

  • 12. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Int J Oncol; 2008 Sep 01; 33(3):433-41. PubMed ID: 18695871
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
    Rich RF, Green WR.
    J Immunol; 2002 Mar 15; 168(6):2751-8. PubMed ID: 11884442
    [Abstract] [Full Text] [Related]

  • 14. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD.
    J Immunol; 1999 Feb 15; 162(4):2227-34. PubMed ID: 9973498
    [Abstract] [Full Text] [Related]

  • 15. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL, Hudson JM, Ross MI, Zhang HZ, Ioannides CG.
    J Immunother; 2000 Jan 15; 23(1):28-35. PubMed ID: 10687135
    [Abstract] [Full Text] [Related]

  • 16. Porcine endothelial cells, unlike human endothelial cells, can be killed by human CTL via Fas ligand and cannot be protected by Bcl-2.
    Zheng L, Ben LH, Pober JS, Bothwell AL.
    J Immunol; 2002 Dec 15; 169(12):6850-5. PubMed ID: 12471117
    [Abstract] [Full Text] [Related]

  • 17. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E.
    J Immunol; 1995 Mar 01; 154(5):2257-65. PubMed ID: 7868898
    [Abstract] [Full Text] [Related]

  • 18. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.
    Cancer Immunol Immunother; 2000 Mar 01; 48(12):661-72. PubMed ID: 10752474
    [Abstract] [Full Text] [Related]

  • 19. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
    Sørensen RB, Junker N, Kirkin A, Voigt H, Svane IM, Becker JC, thor Straten P, Andersen MH.
    Cancer Immunol Immunother; 2009 May 01; 58(5):665-75. PubMed ID: 18828018
    [Abstract] [Full Text] [Related]

  • 20. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.
    Cancer Res; 2003 May 15; 63(10):2535-45. PubMed ID: 12750277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.